Stabilized iRGD modification enhances NY-ESO-1 TCR-T infiltration in solid tumors and synergizes with PD-1 blockade
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04077-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Yirong Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of the Comprehensive Cancer Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, 321 Zhongshan …. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Receptors, Antigen, T-Cell, Neoplasms, Oligopeptides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, the Social Development Fund of Jiangsu Province.
Abstract (Originalsprache)
Currently, two main challenges in cancer immunotherapy commonly hinder the application of T cell receptor-modified T cell (TCR-T) therapy in the treatment of solid tumors, including the limited ability of T cells to infiltrate solid tumor tissues and the immunosuppressive signals that restrain the anti-tumor efficacy of T cells. In this study, we constructed NY-ESO-1-specific TCR-T and introduced polyethylene glycol-phospholipids (PEG-lipids) to stably modify NY-ESO-1 TCR-T with nonapeptide iRGD, aiming to enhance the penetrability of T cells in vivo, then we combined iRGD-modified NY-ESO-1 TCR-T (iRGD-NY-ESO-1 TCR-T) with PD-1 blockade to alleviate immunosuppressive signals. In result, it is suggested that stably modifying NY-ESO-1 TCR-T with iRGD is a simple and effective strategy to enable TCR-T to target and penetrate solid tumor tissues. Besides, the combination of iRGD-NY-ESO-1 TCR-T with PD-1 blockade presents a novel synergistic strategy for the treatment of refractory NY-ESO-1-positive solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of the Comprehensive Cancer Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, 321 Zhongshan Road, Nanjing, 210008, China.
- Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China.
- Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.
- Department of the Comprehensive Cancer Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, 321 Zhongshan Road, Nanjing, 210008, China. zouzhengyun@njglyy.com.
- Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China. zouzhengyun@njglyy.com.
- Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China. zouzhengyun@njglyy.com.
Förderung
- National Natural Science Foundation of China
- the Social Development Fund of Jiangsu Province
Zitieren
APA
Wu, Y., Qin, L., Wang, J., Xie, Z., Su, X., Li, X., Yang, Y., Huang, R., Zhao, M., Zhao, L., & Zou, Z. (2025). Stabilized iRGD modification enhances NY-ESO-1 TCR-T infiltration in solid tumors and synergizes with PD-1 blockade. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04077-1
Vancouver
Wu Y, Qin L, Wang J, Xie Z, Su X, Li X, et al. Stabilized iRGD modification enhances NY-ESO-1 TCR-T infiltration in solid tumors and synergizes with PD-1 blockade. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04077-1
BibTeX
@article{Wu2025,
author = {Wu, Yirong and Qin, Lanqun and Wang, Jiayu and Xie, Ziyao and Su, Xinyu and Li, Xiang and Yang, Yueling and Huang, Rong and Zhao, Mengke and Zhao, Lianjun and Zou, Zhengyun},
title = {Stabilized iRGD modification enhances NY-ESO-1 TCR-T infiltration in solid tumors and synergizes with PD-1 blockade},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04077-1}
}
EUVIMED